Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
Background and aimsAntiretroviral therapy (ART) based on dolutegravir (DTG) has emerged as a critical component in the treatment of HIV infection and is widely utilized in clinical practice. However, the existing post-marketing pharmacovigilance studies on DTG are incomplete; therefore, this study a...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2025-07-01
|
| Серии: | Frontiers in Pharmacology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1625601/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|